Increased Spleen Volume in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab in Comparison to Lenvatinib: A Retrospective Analysis.

Takeshi Hatanaka,Atsushi Naganuma,Ai Furusawa,Yuki Tamura,Naoto Saito,Yuhei Suzuki,Takashi Hoshino,Yutaka Yata,Toshio Uraoka,Satoru Kakizaki

Oncology（2023）

引用 1|浏览4

暂无评分

摘要

Atez/Bev treatment could result in an increased spleen volume. Caution is required when managing patients treated with Atez/Bev, especially those with a high NLR.

查看译文

关键词

Atezolizumab and bevacizumab,Hepatocellular carcinoma,Immune checkpoint inhibitor,Myeloid-derived suppressor cell,Neutrophil-to-lymphocyte ratio,Spleen

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要